Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT03618550). METHODS Transplant eligible patients with rel/ref cHL following first-line therapy were treated with two to four cycles of...

  • Really promising results of a phase II trial looking at Pembro +GVD for relapsed Hodgkin. 95% CR rate, 95% went to Auto, and all are in remission at median f/u of 13.5 months.